Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURKLINIKEN I KATRINEHOLM
Mandate

VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURKLINIKEN I KATRINEHOLM

April 22, 2014

Vinge has advised AniCura (formerly Djursjukhusgruppen) in connection with the acquisition of Djurkliniken i Katrineholm Aktiebolag. AniCura is a leader in advanced veterinary care for dogs, cats and other companion animals. Established in 2011, AniCura is the first merger of companion animal hospitals in the Nordic region and is currently the only Nordic veterinary care group exclusively focused on companion animals.

Vinge’s team consisted of partner Jonas Bergström together with, among others, associates Gustav Jönsson, Erik Claesson, Niclas Winnberg and Emelie Klefbeck.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025